BeOne Medicines (ONC) Short-Term Debt issuances (2017 - 2026)

BeOne Medicines (ONC) has reported Short-Term Debt issuances for 8 consecutive years, with $58.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-Term Debt issuances fell 66.34% year-over-year to $58.2 million; the TTM figure through Mar 2026 stood at $930.1 million (down 10.67% YoY), while the FY2025 annual figure was $1.0 billion, up 20.33% from the prior year.
• Short-Term Debt issuances slipped to $58.2 million in Q1 2026 per ONC's latest filing, from $769.0 million in the prior quarter.
• Across five years, Short-Term Debt issuances topped out at $769.0 million in Q4 2025 and bottomed at -$2.3 million in Q3 2023.
• Historically, Short-Term Debt issuances has averaged $192.7 million across 5 years, with a median of $107.4 million in 2023.
• Annual changes were most pronounced in 2023 — Short-Term Debt issuances plunged 107.56% — and 2024, when it jumped 373.85%.
• BeOne Medicines' Short-Term Debt issuances stood at $271.7 million in 2022, then plunged by 44.78% to $150.0 million in 2023, then surged by 373.85% to $710.8 million in 2024, then increased by 8.19% to $769.0 million in 2025, then slumped by 92.43% to $58.2 million in 2026.
• Business Quant data shows ONC's Short-Term Debt issuances at $58.2 million in Q1 2026, $769.0 million in Q4 2025, and $102.9 million in Q2 2025.